Bio-Techne Corporation
TECHBusiness Overview
source: coverage-next-full ticker: TECH step: "01" title: Business Overview — Bio-Techne Corporation created: 2026-05-29
Step 01 — Business Overview: Bio-Techne Corporation (TECH)
Company Summary
Bio-Techne Corporation is a Minneapolis-based life science tools and diagnostics company that develops, manufactures, and sells proteins, antibodies, immunoassays, and analytical instruments used in biomedical research, drug discovery, and clinical diagnostics. Founded in 1976 (as Techne Corporation) and transformed through a series of strategic acquisitions, Bio-Techne has built one of the most respected reagent portfolios in academic and pharmaceutical research globally.
The company's brand portfolio — anchored by R&D Systems (arguably the gold standard for recombinant proteins and cytokines), Novus Biologicals, and Tocris Bioscience — is deeply embedded in the scientific literature, creating a durable competitive position. Bio-Techne operates as a classic high-margin consumables business: instruments are placed in labs and generate an ongoing pull-through of reagent/assay revenue, mirroring the razor/razor-blade model.
Business Segments
1. Protein Sciences (~75% of Revenue)
The core and heritage business, encompassing:
Reagents & Consumables:
- Recombinant Proteins & Cytokines (R&D Systems brand): Growth factors, cytokines, chemokines used in cell culture, cell therapy manufacturing, and drug discovery. R&D Systems proteins are cited in hundreds of thousands of peer-reviewed publications — a form of scientific switching cost.
- Antibodies: Primary and secondary antibodies for research use; sold under R&D Systems and Novus Biologicals brands
- ELISA Kits / DuoSet: Pre-configured sandwich ELISA kits for measuring protein levels in samples; highly recurring with strong customer retention
- Small Molecules / Biochemicals (Tocris): Pharmacologically active compounds for neuroscience and receptor biology research
Analytical Platforms (Instruments + Consumables):
- Simple Western / Wes (ProteinSimple acquisition): Automated capillary Western blotting — replaces traditional gel-based Western blot with a faster, more reproducible microfluidic format. Instrument + cartridge consumable model.
- Simple Plex / Ella: Multiplex immunoassay platform for measuring panels of proteins; used in clinical research and biologics QC
- Maurice: Capillary electrophoresis system for biologic drug characterization (purity, charge variants)
2. Diagnostics & Genomics (~25% of Revenue)
A higher-growth segment driven by spatial biology:
Genomics:
- RNAscope (Advanced Cell Diagnostics / ACD acquisition, 2016): Fluorescent and chromogenic in situ hybridization (ISH) technology that visualizes individual RNA molecules directly in tissue sections. Key enabling tool for spatial transcriptomics and translational pathology. Competes with 10x Genomics' Visium and Nanostring's CosMx.
- BaseScope / miRNAscope: Extensions of RNAscope for detecting specific RNA splice variants and microRNAs
Clinical Diagnostics:
- Renal Diagnostics (Exosome Diagnostics acquisition): Urinalysis tests for kidney disease monitoring
- Hematology Reagents: Clinical lab reagents sold to hospital diagnostics labs
- Point-of-Care (legacy Bionostics / Utak businesses): Calibrators, controls for clinical chemistry analyzers
Key Brands
| Brand | Heritage | Core Application |
|---|---|---|
| R&D Systems | Founded 1976 | Recombinant proteins, cytokines, ELISAs |
| ProteinSimple | Acquired 2014 | Simple Western, Ella, Maurice platforms |
| Novus Biologicals | Acquired 2014 | Antibodies (broad catalog) |
| Tocris Bioscience | Acquired 2011 | Small molecules, neuroscience reagents |
| Advanced Cell Diagnostics (ACD) | Acquired 2016 | RNAscope spatial biology |
| Exosome Diagnostics | Acquired 2018 | Liquid biopsy / urinalysis |
Geographic Footprint
- Headquarters: Minneapolis, Minnesota
- Manufacturing: Minneapolis (proteins), San Jose, CA (ProteinSimple instruments), Newark, CA (ACD)
- Revenue Split: ~55% United States, ~45% International (Europe, Asia-Pacific, China significant)
- China exposure: ~10-12% of revenue; subject to regulatory and geopolitical sensitivity
Employees
Approximately 2,900–3,100 employees globally (as of FY2024). R&D-heavy workforce; significant PhD-level scientific staff.
What Makes Bio-Techne Distinctive
Citation moat: R&D Systems proteins are the most-cited reagent brand in scientific literature. Scientists who publish with a specific lot of R&D Systems cytokine re-order the same product to maintain experimental reproducibility — an extraordinarily sticky customer relationship.
Platform breadth at premium quality: Bio-Techne doesn't compete on price; it competes on product quality, technical support, and catalog breadth. Premium pricing is sustained by the reproducibility imperative in research.
Spatial biology optionality: RNAscope is positioned at the intersection of spatial transcriptomics and clinical pathology — a market that could scale significantly as single-cell and spatial biology tools become standard in drug development and diagnostics.
Cell therapy tailwinds: R&D Systems cytokines and growth factors are increasingly used in the manufacturing of CAR-T and other cell therapies. As cell therapy commercializes, this creates a GMP-grade reagent opportunity beyond research use.
Financial Snapshot
source: coverage-next-full ticker: TECH step: "04" title: Financial Snapshot — 3-Year P&L Summary created: 2026-05-29
Step 04 — Financial Snapshot: 3-Year P&L Summary
Income Statement Summary (FY2022–FY2024)
Fiscal year ends June 30. All figures in millions USD unless noted.
| Metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Revenue | $1,056M | $1,102M | $1,104M |
| YoY Growth | +14.0% | +4.4% | +0.2% |
| Gross Profit | $794M | $820M | $817M |
| Gross Margin | 75.2% | 74.4% | 74.0% |
| R&D Expense | $65M | $70M | $72M |
| R&D as % Revenue | 6.2% | 6.4% | 6.5% |
| SG&A Expense | $240M | $258M | $255M |
| SG&A as % Revenue | 22.7% | 23.4% | 23.1% |
| GAAP Operating Income | $348M | $325M | $303M |
| GAAP Operating Margin | 33.0% | 29.5% | 27.4% |
| Adjusted Operating Income | ~$425M | ~$415M | ~$400M |
| Adjusted Operating Margin | ~40.2% | ~37.7% | ~36.2% |
| GAAP Net Income | $285M | $248M | $235M |
| Adjusted Net Income | ~$350M | ~$335M | ~$318M |
| GAAP Diluted EPS | $7.18 | $6.26 | $5.94 |
| Adjusted Diluted EPS | ~$8.82 | ~$8.46 | ~$8.04 |
| EBITDA (Adjusted) | ~$460M | ~$450M | ~$435M |
| Adjusted EBITDA Margin | ~43.6% | ~40.8% | ~39.4% |
Notes: GAAP vs. adjusted differences primarily reflect stock-based compensation ($50-60M), amortization of acquired intangibles ($70-80M), and restructuring charges. Adjusted figures are non-GAAP management metrics.
Key Profitability Trends
Gross Margin Compression
Bio-Techne's gross margin has been remarkably stable in the 73-76% range over the past several years, reflecting:
- Premium pricing power
- Reagent-heavy mix (reagents carry 80%+ gross margins)
- Offset by instrument mix (instruments carry lower gross margins, ~45-55%)
- Small dilution from acquired businesses with slightly lower margins
The ~1-2pp compression from FY2022 to FY2024 is modest and primarily reflects:
- Higher instrument revenue mix as new platforms ramped
- Some volume deleverage on fixed manufacturing costs
- Inflation in raw materials (partially offset by price increases)
Operating Margin Dynamics
GAAP operating margins compressed from ~33% in FY2022 to ~27% in FY2024 due to:
- Revenue growth slowdown (volume deleverage)
- Continued investment in sales force and R&D
- Higher amortization from recent acquisitions
- Integration costs
Adjusted operating margins (~36-40%) are more representative of the underlying business economics and remain best-in-class for the sector.
EPS Trajectory
Adjusted EPS peaked in FY2022 and has declined through FY2024, reflecting:
- Revenue deceleration (primary driver)
- Modest operating leverage loss
- Higher interest expense (acquisitions funded partly with debt)
- Partially offset by share buybacks
Balance Sheet Highlights (FY2024)
| Item | Value |
|---|---|
| Total Assets | ~$4.3B |
| Total Goodwill & Intangibles | ~$2.8B |
| Cash & Equivalents | ~$60-80M |
| Total Debt (gross) | ~$1.1-1.2B |
| Net Debt | ~$1.0-1.1B |
| Total Equity | ~$2.9B |
The large goodwill/intangibles balance reflects the acquisition-driven growth strategy (ProteinSimple, ACD/RNAscope, Exosome Diagnostics, etc.).
Cash Flow Summary
| Metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Operating Cash Flow | ~$390M | ~$355M | ~$340M |
| Capex | ~$(50)M | ~$(55)M | ~$(50)M |
| Free Cash Flow | ~$340M | ~$300M | ~$290M |
| FCF Margin | ~32% | ~27% | ~26% |
| FCF Conversion (of adj. net income) | ~97% | ~90% | ~91% |
Bio-Techne is a strong free cash flow generator — FCF conversion above 90% of adjusted net income reflects the asset-light nature of the reagent manufacturing business. Capital expenditures are primarily for lab/manufacturing equipment and facility maintenance.
Valuation Multiples (as of early 2026)
| Metric | Value |
|---|---|
| Share Price (approx.) | ~$55-65 |
| Market Cap | ~$2.1-2.5B |
| Enterprise Value | ~$3.1-3.5B |
| EV/Revenue (FY2024) | ~2.8-3.2x |
| EV/EBITDA (adj., FY2024) | ~7-8x |
| P/E (adj., FY2024) | ~7-8x |
| EV/EBIT (adj., FY2024) | ~8-9x |
Note: These represent significant multiple compression from peak (FY2021 EV/EBITDA was ~30-35x). The stock de-rated substantially as growth slowed and rates rose.
Segment Profitability
Bio-Techne reports segment operating income (before corporate allocations):
| Segment | FY2024 Op. Income | Segment Margin |
|---|---|---|
| Protein Sciences | ~$375M | ~45% |
| Diagnostics & Genomics | ~$25M | ~9% |
The stark margin differential reflects:
- Protein Sciences: Mature, high-margin reagent business with strong operating leverage
- Diagnostics & Genomics: Earlier-stage platforms (RNAscope, Ella) still scaling; higher investment in commercialization, R&D
As RNAscope/spatial biology scales, D&G margin should improve substantially over time — this is a key source of potential earnings upside.
Key Financial Ratios
| Ratio | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Gross Margin | 75.2% | 74.4% | 74.0% |
| Adj. EBITDA Margin | 43.6% | 40.8% | 39.4% |
| FCF Margin | 32% | 27% | 26% |
| Net Debt/EBITDA | ~1.0x | ~1.2x | ~1.4x |
| Interest Coverage (EBIT/interest) | ~15x | ~12x | ~10x |
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $TECH.